JP2019520340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520340A5 JP2019520340A5 JP2018562993A JP2018562993A JP2019520340A5 JP 2019520340 A5 JP2019520340 A5 JP 2019520340A5 JP 2018562993 A JP2018562993 A JP 2018562993A JP 2018562993 A JP2018562993 A JP 2018562993A JP 2019520340 A5 JP2019520340 A5 JP 2019520340A5
- Authority
- JP
- Japan
- Prior art keywords
- faecalibacterium
- pharmaceutical composition
- microbial preparation
- purified
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001608234 Faecalibacterium Species 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 230000000813 microbial effect Effects 0.000 claims 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 9
- 229940100691 oral capsule Drugs 0.000 claims 8
- 230000002550 fecal effect Effects 0.000 claims 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 6
- 241000605909 Fusobacterium Species 0.000 claims 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 3
- 108010024636 Glutathione Proteins 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 3
- 241000192031 Ruminococcus Species 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 235000018417 cysteine Nutrition 0.000 claims 3
- 229960002433 cysteine Drugs 0.000 claims 3
- 235000013325 dietary fiber Nutrition 0.000 claims 3
- 229960003180 glutathione Drugs 0.000 claims 3
- 235000003969 glutathione Nutrition 0.000 claims 3
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 3
- 235000010987 pectin Nutrition 0.000 claims 3
- 229920001277 pectin Polymers 0.000 claims 3
- 239000001814 pectin Substances 0.000 claims 3
- 229960000292 pectin Drugs 0.000 claims 3
- 235000019192 riboflavin Nutrition 0.000 claims 3
- 229960002477 riboflavin Drugs 0.000 claims 3
- 239000002151 riboflavin Substances 0.000 claims 3
- 241000702460 Akkermansia Species 0.000 claims 2
- 241000701474 Alistipes Species 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 241000606125 Bacteroides Species 0.000 claims 2
- 241000605947 Roseburia Species 0.000 claims 2
- 241001531188 [Eubacterium] rectale Species 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003324 growth hormone secretagogue Substances 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344053P | 2016-06-01 | 2016-06-01 | |
| US62/344,053 | 2016-06-01 | ||
| PCT/US2017/035449 WO2017210428A1 (en) | 2016-06-01 | 2017-06-01 | Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019520340A JP2019520340A (ja) | 2019-07-18 |
| JP2019520340A5 true JP2019520340A5 (OSRAM) | 2020-08-13 |
Family
ID=60479147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562993A Pending JP2019520340A (ja) | 2016-06-01 | 2017-06-01 | 炎症性腸疾患（ｉｂｄ）および他の障害を治療するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20170348360A1 (OSRAM) |
| EP (1) | EP3462882A4 (OSRAM) |
| JP (1) | JP2019520340A (OSRAM) |
| CN (1) | CN109803534A (OSRAM) |
| AU (1) | AU2017274416C1 (OSRAM) |
| CA (1) | CA3026414A1 (OSRAM) |
| WO (1) | WO2017210428A1 (OSRAM) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160339065A1 (en) | 2015-05-22 | 2016-11-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for Treating Autism Spectrum Disorder and Associated Symptoms |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
| CA3058943C (en) | 2017-04-03 | 2023-10-17 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
| WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| AU2018250206A1 (en) | 2017-04-05 | 2019-10-31 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (PD) and related disorders |
| EP3630190B1 (en) | 2017-05-26 | 2024-02-21 | Finch Therapeutics Holdings LLC | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| CN111107860A (zh) * | 2017-06-16 | 2020-05-05 | 表飞鸣制药株式会社 | 脂肪相关疾病和/或炎症的预防或治疗剂 |
| US20200268017A1 (en) * | 2017-06-20 | 2020-08-27 | Cornell University | Probiotic compositions and methods |
| WO2019032573A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER |
| AU2018379996A1 (en) | 2017-12-05 | 2020-06-25 | BioPlx, Inc. | Methods and compositions to prevent microbial infection |
| CN111479579A (zh) * | 2017-12-12 | 2020-07-31 | 森永乳业株式会社 | 以双歧杆菌属细菌作为有效成分的组合物 |
| GB2585291B (en) * | 2018-02-02 | 2023-07-19 | Univ Hong Kong Chinese | Fecal fungome and therapeutic efficacy of fecal microbiota transplantation |
| WO2019157566A1 (en) * | 2018-02-16 | 2019-08-22 | St Vincent's Hospital (Melbourne) Limited | Compositions and methods for promoting gut health |
| US20210177916A1 (en) * | 2018-04-13 | 2021-06-17 | Med-Life Discoveries Lp | Long chain dicarboxylic fatty acid (lcdfa) producing microbes and uses thereof |
| CN110396538B (zh) * | 2018-04-24 | 2023-05-23 | 深圳华大生命科学研究院 | 偏头痛生物标志物及其用途 |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| EP3870691A4 (en) * | 2018-09-13 | 2022-09-07 | Xbiome Inc. | METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS |
| JP2022514145A (ja) | 2018-09-27 | 2022-02-10 | フィンチ セラピューティクス ホールディングス エルエルシー | てんかんおよび関連する障害を治療するための組成物および方法 |
| US20220218761A1 (en) * | 2019-05-06 | 2022-07-14 | The General Hospital Corporation | Monitoring and altering the gut microbiome in disease |
| AU2020310947A1 (en) * | 2019-07-11 | 2021-12-23 | Thomas Julius Borody | Method for gut mucosa preparation to enhance microbial engraftment |
| BR112022000875A2 (pt) | 2019-07-19 | 2022-03-29 | Finch Therapeutics Holdings Llc | Métodos e produtos para tratamento de distúrbios gastrointestinais |
| CN110541026A (zh) * | 2019-08-17 | 2019-12-06 | 昆明医科大学第一附属医院 | 一种检测溃疡性结肠炎的生物标志物及应用 |
| EP4045069A1 (en) * | 2019-10-18 | 2022-08-24 | Thaena Inc. | Fecal-derived sterile postbiotic composition and method therefor |
| EP3838276A1 (en) * | 2019-12-17 | 2021-06-23 | Exeliom Biosciences | Association of faecalibacterium prausnitzii strain cncm i-4573 with pentasa® for the treatment and prevention of gastrointestinal inflammation |
| EP3839072A1 (en) * | 2019-12-17 | 2021-06-23 | Luxia Scientific | Bacterial combinations predictive of the activity of multiple sclerosis |
| US20220408780A1 (en) * | 2020-02-11 | 2022-12-29 | The E. Wolfson Medical Center | A method effective for treating ulcerative colitis |
| WO2021163672A1 (en) * | 2020-02-14 | 2021-08-19 | Cornell University | Transferable microbiota for the treatment of ulcerative colitis |
| CN111304120B (zh) * | 2020-02-24 | 2021-07-23 | 浙江大学 | Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用 |
| EP3875098A1 (en) * | 2020-03-04 | 2021-09-08 | Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement | Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases |
| US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
| AU2021249556A1 (en) * | 2020-04-01 | 2022-10-27 | The E. Wolfson Medical Center | Ulcerative colitis diet, formulae, products and methods thereof |
| EP4161541A4 (en) * | 2020-06-09 | 2024-09-11 | Flagship Pioneering Innovations VI, LLC | PHYSIOLOGICALLY ACCEPTABLE COMPOSITIONS CONTAINING MICROORGANISMS OR MICROBIAL PRODUCTS |
| KR102169794B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도 |
| KR102169795B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도 |
| CA3186783A1 (en) * | 2020-07-30 | 2022-02-03 | John A. KALLASSY | Methods and compositions for treating metabolic conditions |
| CN111888381A (zh) * | 2020-09-18 | 2020-11-06 | 广西细微生物科技有限责任公司 | 一种肠道微生物移植工艺 |
| KR102700146B1 (ko) * | 2020-09-28 | 2024-08-28 | 씨제이바이오사이언스 주식회사 | 미생물을 포함하는 염증성 질환 진단 또는 치료용 조성물 |
| EP4314766A4 (en) * | 2021-04-01 | 2025-05-07 | Medibeacon Inc. | METHODS FOR MONITORING MUCOSA HEALING |
| EP4082545A1 (en) * | 2021-04-27 | 2022-11-02 | Diotheris | Combination product and methods for preventing the emergence of antibiotic-resistant bacteria under antibiotic treatment |
| KR102337993B1 (ko) * | 2021-10-27 | 2021-12-14 | 주식회사 바이오뱅크힐링 | 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| CN113974159B (zh) * | 2021-11-02 | 2023-06-27 | 美益添生物医药(武汉)有限公司 | 齿叶乳香树树脂在制备促进肠道有益菌增殖的产品中的应用 |
| TW202400235A (zh) * | 2022-05-13 | 2024-01-01 | 國立大學法人東京大學 | 治療或診斷炎症性腸疾病(ibd)之方法及組合物 |
| CN115944655A (zh) * | 2023-02-14 | 2023-04-11 | 上海奇诺普森生物科技有限责任公司 | 一种肠菌组合物及其在防治自闭症中的应用 |
| CN119970806A (zh) * | 2025-02-25 | 2025-05-13 | 浙江大学 | 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用 |
| CN119709558B (zh) * | 2025-02-26 | 2025-05-30 | 昆明医科大学第一附属医院(云南省皮肤病医院) | 布劳特氏菌emf75-02b1b及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1510821A1 (en) * | 2003-08-27 | 2005-03-02 | Universiteit Utrecht Holding B.V. | Diagnosis and treatment of mycobacterial infections |
| CA2807242C (en) * | 2010-08-04 | 2017-05-02 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| AU2012225305B2 (en) * | 2011-03-09 | 2017-06-08 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| ES2662793T3 (es) * | 2011-09-14 | 2018-04-09 | Nubiyota Llc | Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos |
| AU2013338774B2 (en) * | 2012-11-01 | 2017-03-02 | Academisch Ziekenhuis Groningen | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract |
| HK1218559A1 (zh) * | 2013-02-04 | 2017-02-24 | Seres Therapeutics, Inc. | 抑制致病细菌生长的配方和方法 |
| MX2015011700A (es) * | 2013-03-05 | 2016-07-20 | Univ Groningen | Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion. |
| US20150246081A1 (en) * | 2014-03-03 | 2015-09-03 | Shayne Kenneth Morris | Probiotics with methods for growth and use separately and in combination |
| US9783858B2 (en) * | 2014-04-02 | 2017-10-10 | Northwestern University | Altered microbiome of chronic pelvic pain |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
-
2017
- 2017-06-01 CA CA3026414A patent/CA3026414A1/en not_active Abandoned
- 2017-06-01 AU AU2017274416A patent/AU2017274416C1/en active Active
- 2017-06-01 US US15/611,338 patent/US20170348360A1/en not_active Abandoned
- 2017-06-01 WO PCT/US2017/035449 patent/WO2017210428A1/en not_active Ceased
- 2017-06-01 EP EP17807481.1A patent/EP3462882A4/en not_active Withdrawn
- 2017-06-01 JP JP2018562993A patent/JP2019520340A/ja active Pending
- 2017-06-01 CN CN201780043664.8A patent/CN109803534A/zh active Pending
-
2020
- 2020-12-28 US US17/135,544 patent/US20210106629A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520340A5 (OSRAM) | ||
| Ojetti et al. | The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial | |
| Bergogne-Berezin | Treatment and prevention of antibiotic associated diarrhea | |
| JP2016529309A5 (OSRAM) | ||
| JP2019525944A5 (OSRAM) | ||
| RU2011139211A (ru) | Бактериальные штаммы, обладающие высокой противовоспалительной активностью | |
| BRPI0517273B1 (pt) | composição contendo uma mistura de três bactérias probióticas, uso desta para a prevenção e/ou tratamento de infecções do trato respiratório superior e na regularização da funcionalidade intestinal do organismo acometido por essas patologias e kit contendo uma mistura de três bactérias probióticas | |
| BR112012018813B1 (pt) | composição compreendendo cepas bacterianas com atividade anti-inflamatória, imunomoduladora, antiibs ou antidistensão abdominal, uso das mesmas, bem como produtos farmacêutico, veterinário e comestível compreendendo a referida composição | |
| BR112020018360A2 (pt) | Composições para uso no equilíbrio do microbioma | |
| US11433102B2 (en) | Compositions and methods for treating Parkinson's disease (PD) and related disorders | |
| US11801275B2 (en) | Compositions and methods for common colds | |
| BR112020019979A2 (pt) | Composições e métodos para tratamento de doenças inflamatórias intestinais | |
| CN116367823A (zh) | 直接递送维生素以抑制微生物病原体 | |
| ITMI950378A1 (it) | Associazioni di fermenti lattici e lisati di saccaromiceti loro uso terapeutico e composizioni che le contengono | |
| US10960034B2 (en) | MRSA infection protective agent | |
| WO2021097288A1 (en) | Compositions and methods for treating neurodegenerative diseases | |
| Schultz et al. | Escherichia coli Nissle 1917 | |
| CN111491643B (zh) | 预防或治疗耐药感染的含益生菌和益生元的药物组合物 | |
| CN114585380A (zh) | 胃肠健康组合物 | |
| US20230404970A1 (en) | Direct delivery of vitamins to rebalance gut microbiome after exposure to antibiotics | |
| US20180289745A1 (en) | Compositions and Methods for Treating Parkinson's Disease (PD) and Related Disorders | |
| CN111436612A (zh) | 一种体内酵素及其制备方法与在抑制新型病毒方面的应用 | |
| RU2614730C1 (ru) | Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза | |
| EP3979834B1 (fr) | Composition comprenant une levure pour la prevention de la cystite simple et/ou recidivante | |
| Telaku et al. | Impact of Lactobacillus Reuteri and Three Other Probiotics in Helicobacter Pylori Eradication. Open Access Maced J Med Sci. 2022 Oct 27; 10 (B): 2215-2219 |